Genzyme lands $345M acquisition of Bioenvision

Genzyme is laying claim to the keys to Bioenvision after winning shareholders' approval of the $345 million buyout. SCO Capital Partners, which owns 13 percent of Bioenvision, had fought the deal, saying that the bid undervalued the company. That argument failed to sway a majority of shareholders, though, who are getting $5.60 a share. Genzyme walks away with all the rights to the cancer drug clofarabine, which it co-developed with Bioenvision.

- take a look at the release
- read the report from the International Herald Tribune

Related Articles:
Bioenvision shareholders shun Genzyme takeover bid. Report
Who's next on the biotech buyout hit list? Report
Genzyme wins bidding war for AnorMED. Report
Boston officials herald big Genzyme expansion. Report

Suggested Articles

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.